Reduced frequency of gestoses in beta-mimetic treated risk pregnancies with added magnesium therapy

Retrospectively the 4,905 single pregnancies of the four years 1979-1982 are divided into 882 (18.0%) patients treated by tocolysis and 4,023 (82.0%) patients treated without tocolysis (R). The patients with tocolysis (BMG) received in addition to the Betamimectic agents since 1979 a low dose of magnesium (feto- longoral ) to protect the heart (3-6 mval Mg ++) daily and since early in 1981 to assist in the tocolysis 30 to 40 mval Mg ++ daily in the oral from of magnesium aspartate (Mg 5- Longoral ). The incidence of pre-eclampsia (G) in the groups BMG and R is recorded. The R group constitutes the normal group (N) by substracting the group G. Compared were in the groups NG and BMG the mean age and parity, the incidence of adjuvant magnesium medication, the duration of pregnancy and the incidence of intra-uterine growth retardation ( IUR ). The incidence of pre-eclampsia (G) in the 882 patients treated with Betamimetics and magnesium was 0. In the other 4,093 patients the incidence was 97 (2%). The rate of intra-uterine growth (lower than the 10% BPE ) was 9.4% in the 3,093 normal patients, 45.4% in the 97 patients with pre-eclampsia and in the 398 BMG patients of the years 1979 and 1980 with the small addition of magnesium (BMG 1) the incidence was 17.8%. In the 484 patients of the years 1981 and 1982, with large additional doses of magnesium (BMG 2) the incidence was 10.1%. The correlation of the intra-uterine growth retardation degrees (lower than 25% Hohenauer , 10% BPE ) was highest in the group G (1.3:1).